Coenzyme Q10 for Gulf War Illness: A Replication Study

a study on Gulf War Syndrome Mitochondrial Disorder, Respiratory Chain

Summary

Eligibility
for people ages 50 years and up (full criteria)
Location
at La Jolla, California
Dates
study started
completion around
Principal Investigator
by Beatrice A Golomb, MD, PhD

Description

Summary

The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.

Keywords

Gulf War Syndrome, Persian Gulf Syndrome, Mitochondrial Disorder, Respiratory Chain, Mitochondrial Diseases, Syndrome, Coenzyme Q10, Ubiquinone, PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

Eligibility

You can join if…

Open to people ages 50 years and up

  • Meets both CDC and Kansas deployment and symptom inclusion criteria.
  • Does not have a disqualifying condition.
  • Able to travel to a local Quest facility for study blood draws.
  • Adequate internet access to allow ZoomPro visit participation and remote survey completion.
  • Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).
  • Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.

You CAN'T join if...

  • Participating in another clinical trial.
  • Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.
  • On Coumadin/ warfarin.
  • Unable to participate for the required duration of the study.

Location

  • UC San Diego accepting new patients
    La Jolla California 92093 United States

Lead Scientist at UCSD

  • Beatrice A Golomb, MD, PhD
    Professor In Residence, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 103 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT06515184
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 192 study participants
Last Updated
Contact us about this trial